IMPACT OF GLUCOSAMINE ON THE BURDEN OF KNEE OSTEOARTHRITIS OVER A 6 MONTH-PERIOD IN FRANCE- AN OBSERVATIONAL STUDY

Author(s)

Hemery R¹, Zkik A², Auges M³, Chalem Y⁴
¹Pierre Fabre médicament, castres, France, ²Pierre Fabre, Boulogne Billancourt, France, ³Pierre Fabre, boulogne billancourt, France, ⁴Pierre Fabre, Boulogne-Billancourt, France

OBJECTIVES: OsteoArthritis (OA) is a chronic disease characterized by a progressive degradation of the joint, especially cartilage. Therefore, the disease progression and associated disabilities may severely impact the patients’ mobility and quality of life. Among the different locations OA of the knee is one of the most disabling. The prevalence of knee OA has been estimated in France at 7.6%, corresponding to a total population of 2 million patients. The objectives of this study aims to evaluate the impact of a glucosamine treatment on the symptoms and evolution of gonarthrosis, through the BONe’S (Burden Osteoarthritis New Scale) questionnaire and an assessment of pain relief during 6 months of treatment. METHODS: An observational, prospective longitudinal study was conducted in France from 2013 to 2015. Physicians were required to include, the first 5 patients to whom they prescribed glucosamine and who met the eligibility criteria. Data collected at inclusion, 1, 3 and 6 months, consisted in demographic characteristics, clinical information, and pain of gonarthrosis (VAS), type of medication, BONe’S questionnaire, health status and compliance. RESULTS:

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PMS72

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic

Patient-Centered Research

Presentation